{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:46:14Z","timestamp":1791805574352,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","award":["IRB202301358"],"award-info":[{"award-number":["IRB202301358"]}],"id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtha.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:51:24Z","timestamp":1747223484000},"page":"2651-2655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Akshay","family":"Mathavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3496-2542","authenticated-orcid":false,"given":"Akash","family":"Mathavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Krekora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krunal","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Zumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-1680","authenticated-orcid":false,"given":"Ali","family":"Ataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.05.007_bib2","article-title":"An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms","volume":"9","author":"Arthur","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11547-012-0789-3","article-title":"Hepatic nodular regenerative lesions in patients with hereditary haemorrhagic telangiectasia: computed tomography and magnetic resonance findings","volume":"118","author":"Scardapane","year":"2013","journal-title":"Radiol Med"},{"key":"10.1016\/j.jtha.2025.05.007_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12301","article-title":"Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review","volume":"13","author":"Mathavan","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jtha.2025.05.007_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J Intern Med"},{"key":"10.1016\/j.jtha.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.3390\/jcm13185404","article-title":"The role of thalidomide and its analogs in the treatment of hereditary hemorrhagic telangiectasia: a systematic review","volume":"13","author":"Ugur","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2024-206244","article-title":"A randomized, placebo-controlled, multicenter proof-of-concept (POC) study to assess the safety and efficacy of the novel allosteric AKT inhibitor, VAD044, in adults with hereditary hemorrhagic telangiectasia (HHT)","volume":"144","author":"Al-Samkari","year":"2024","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.jtha.2025.05.007_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-191983","article-title":"PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life","volume":"142","author":"Al-Samkari","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jamadermatol.2021.5132","article-title":"Improvement of cutaneous hereditary hemorrhagic telangiectasia with pazopanib\u2014a multikinase inhibitor","volume":"158","author":"Moon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtha.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jtha.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure","volume":"68","author":"Reddy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.05.007_bib14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"Al-Samkari","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/bjc.2011.81","article-title":"Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration","volume":"104","author":"Fan","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtha.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.05.007_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtha.2025.05.007_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jama.2023.22990","article-title":"Progressive dyspnea on exertion in an 82-year-old","volume":"331","author":"Mathavan","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijo.IJO_459_20","article-title":"One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders","volume":"69","author":"Salimi","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtha.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/medicina59091533","article-title":"Aflibercept for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: a case report","volume":"59","author":"Villanueva","year":"2023","journal-title":"Medicina (B Aires)"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:47:05Z","timestamp":1785552425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1538783625003216"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.007","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}